ArticleOncoTargets and therapy2016
Quantitative assessment of caveolin-1 G14713A polymorphism and cancer susceptibility in the Asian population.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe relationship between caveolin-1 (CAV1) G14713A polymorphism and cancer susceptibility remains inconclusive. The current meta-analysis was performed on the basis of a systematic search in electronic databases for a more precise estimation of the associations.
methodsOdds ratio (OR) with 95% confidence interval (CI) was used to estimate the pooled effect.
resultsA total of 12 studies including 4,994 cases and 5,606 controls were involved in this meta-analysis. In the overall analysis, CAV1 G14713A polymorphism was significantly associated with an increased risk of cancer (A vs G: OR =1.77, 95% CI: 1.49-2.10, P het<0.01; [AA + AG] vs GG: OR =2.03, 95% CI: 1.64-2.53, P het<0.01; AA vs [AG + GG]: OR =1.72, 95% CI: 1.40-2.12, P het<0.01; AA vs GG: OR =2.24, 95% CI: 1.69-2.98, P het<0.01; AG vs GG: OR =1.98, 95% CI: 1.62-2.41, P het<0.01). Subgroup analysis by cancer type showed that CAV1 G14713A polymorphism was associated with an increased risk of digestive system cancer and other cancer types.
conclusionOur findings suggest that CAV1 G14713A polymorphisms may modify the risk of cancer, especially digestive system cancer. However, further well-designed studies are warranted to validate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.